Adele Blackler, Ph.D.
About Adele Blackler, Ph.D.
Adele Blackler, Ph.D., is the Vice President of Platform Development with expertise in mass spectrometry, oncology liquid biopsy tests, and clinical proteomic applications, focusing on the development of diagnostic tests for solid tumors.
Adele Blackler, Ph.D. - Vice President of Platform Development
Adele Blackler serves as the Vice President of Platform Development. She has a rich background in diagnostic technologies and has been instrumental in the development of innovative tests for oncology and other applications. Her role involves overseeing the development of new assays and guiding initiatives to leverage advanced platforms for disease detection and treatment support.
Education and Expertise in Chemistry and Proteomics
Adele Blackler earned her bachelor's degree in chemistry from the Colorado School of Mines. She advanced her studies at the University of Colorado, at Anschutz, where she obtained her Ph.D. Her doctoral research focused on creating high-throughput proteomic methods for analyzing membrane proteins. Her post-doctoral fellowship at the National Cancer Institute further honed her expertise in high-throughput protein analysis combined with tissue microdissection techniques.
Experience in Mass Spectrometry and Clinical Proteomic Applications
Adele Blackler possesses extensive experience in mass spectrometry and clinical proteomics. Her work has spanned various diagnostic companies where she developed multiplex biomarker tests. These tests are crucial for supporting therapeutic decisions, particularly in the treatment of solid tumors such as lung, colorectal, and breast cancer.
Development of Multiplex Biomarker Tests and Companion Diagnostics
Throughout her career, Adele Blackler has worked on single site Laboratory Developed Tests using proteomic and genomic platforms. She also contributed to Clinical Trial Assays serving as companion diagnostics to guide lung cancer therapy. Her work in these areas highlights her expertise in creating tests that help in making therapeutic decisions.
Innovation in Assay Development for Disease Signatures
In her current role, Adele Blackler oversees the development of assays aimed at detecting and quantifying gangliosides. These assays are designed to identify disease signatures, enhancing diagnostic capabilities and offering new insights into various medical conditions. Her work drives forward the potential for innovative diagnostic tests that can significantly impact patient care.